CN110354144A - Rich in the ascidian extract of a variety of plasmalogens and its preparation and analysis method - Google Patents
Rich in the ascidian extract of a variety of plasmalogens and its preparation and analysis method Download PDFInfo
- Publication number
- CN110354144A CN110354144A CN201910757992.5A CN201910757992A CN110354144A CN 110354144 A CN110354144 A CN 110354144A CN 201910757992 A CN201910757992 A CN 201910757992A CN 110354144 A CN110354144 A CN 110354144A
- Authority
- CN
- China
- Prior art keywords
- ascidian
- plasmalogens
- plasmalogen
- variety
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000251557 Ascidiacea Species 0.000 title claims abstract description 66
- 239000000284 extract Substances 0.000 title claims abstract description 41
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 238000004458 analytical method Methods 0.000 title abstract description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims abstract description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000006228 supernatant Substances 0.000 claims abstract description 10
- 238000000034 method Methods 0.000 claims abstract description 9
- 239000007791 liquid phase Substances 0.000 claims abstract description 6
- 239000000047 product Substances 0.000 claims abstract description 6
- 239000004615 ingredient Substances 0.000 claims abstract description 5
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 claims abstract description 5
- 239000002994 raw material Substances 0.000 claims abstract description 5
- 230000032683 aging Effects 0.000 claims abstract description 4
- 230000006806 disease prevention Effects 0.000 claims abstract description 4
- 238000009509 drug development Methods 0.000 claims abstract description 4
- 230000036541 health Effects 0.000 claims abstract description 4
- 239000002417 nutraceutical Substances 0.000 claims abstract description 4
- 235000021436 nutraceutical agent Nutrition 0.000 claims abstract description 4
- 239000003960 organic solvent Substances 0.000 claims abstract description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 16
- 239000000843 powder Substances 0.000 claims description 14
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims description 13
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims description 12
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 9
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
- 238000005119 centrifugation Methods 0.000 claims description 6
- 150000003904 phospholipids Chemical class 0.000 claims description 6
- 239000003963 antioxidant agent Substances 0.000 claims description 4
- 230000003078 antioxidant effect Effects 0.000 claims description 4
- 238000004587 chromatography analysis Methods 0.000 claims description 3
- 238000007710 freezing Methods 0.000 claims description 3
- 230000008014 freezing Effects 0.000 claims description 3
- 238000000227 grinding Methods 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 210000001835 viscera Anatomy 0.000 claims description 3
- 238000004140 cleaning Methods 0.000 claims description 2
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 2
- 238000007781 pre-processing Methods 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 238000010790 dilution Methods 0.000 claims 1
- 239000012895 dilution Substances 0.000 claims 1
- 238000001819 mass spectrum Methods 0.000 claims 1
- 238000010183 spectrum analysis Methods 0.000 abstract description 7
- 238000000605 extraction Methods 0.000 abstract description 4
- 230000020477 pH reduction Effects 0.000 abstract description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical group CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 14
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 12
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 8
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 8
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 8
- 239000000203 mixture Substances 0.000 description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 6
- 229940090949 docosahexaenoic acid Drugs 0.000 description 6
- 150000001768 cations Chemical class 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- 208000024827 Alzheimer disease Diseases 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- -1 phosphatidalcholine Chemical compound 0.000 description 4
- 241000251511 Holothuroidea Species 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 241000251556 Chordata Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 241000251555 Tunicata Species 0.000 description 2
- 150000001336 alkenes Chemical class 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000009514 concussion Effects 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 230000002949 hemolytic effect Effects 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 206010053684 Cerebrohepatorenal syndrome Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000251591 Halocynthia roretzi Species 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 102000011420 Phospholipase D Human genes 0.000 description 1
- 108090000553 Phospholipase D Proteins 0.000 description 1
- 238000012356 Product development Methods 0.000 description 1
- 201000004525 Zellweger Syndrome Diseases 0.000 description 1
- 208000036813 Zellweger spectrum disease Diseases 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000009360 aquaculture Methods 0.000 description 1
- 244000144974 aquaculture Species 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- SIHHLZPXQLFPMC-UHFFFAOYSA-N chloroform;methanol;hydrate Chemical compound O.OC.ClC(Cl)Cl SIHHLZPXQLFPMC-UHFFFAOYSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 208000018875 hypoxemia Diseases 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000037427 ion transport Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L17/00—Food-from-the-sea products; Fish products; Fish meal; Fish-egg substitutes; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/616—Echinodermata, e.g. starfish, sea cucumbers or sea urchins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/72—Mass spectrometers
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Nutrition Science (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Marine Sciences & Fisheries (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a kind of rich in the ascidian extract of a variety of plasmalogens and its preparation and analysis method.This method is extracted as raw material using certain proportion water mixed organic solvents using cheap ascidian, and recycles remaining Plasmalogens in supernatant, is significantly increased extraction efficiency, is improved the extracted amount of plasmalogen；Show that extract prepared by the present invention includes a variety of plasmalogen ingredients and polyunsaturated fatty acid DHA and EPA using the type of mass spectral analysis plasmalogen to analyze the content of plasmalogen in extract with hydrochloric acid acidification 5min before high-efficient liquid phase analysis.Raw material can be used as fields such as nutraceutical, the relevant health care product of aging disease prevention and cure and drug developments using the ascidian extract rich in a variety of plasmalogens prepared by the method for the present invention.
Description
Technical field
The invention belongs to Food Chemistries and biomedicine field, and in particular to the ascidian extract rich in a variety of plasmalogens
And its preparation and analysis method.
Background technique
Plasmalogen is that a kind of special phosphatide represents, and accounts for about the 10% of cell total phospholipids, it is that one kind contains alkene ehter bond
Glycerophosphatide, such as phosphatidal ethanolamine, phosphatidalcholine, phosphatidalserine.It is mainly characterized by
Sn-1 contains position alkene ehter bond, and is usually connected to c16:0 in mammals；The fatty alcohol of 18:0 or 18:1, on sn-2
It is mostly the polyunsaturated fatty acid of n-3 and n-6.The rich content in the organs such as brain, heart.Plasmalogen its most of concentrate
It is distributed in biomembrane " Lipid Rafts " structure, participates in cell fusion, ion transport and the transport of cholesterol, while can also be used as matter
Important antioxidant on film, avoids the damage of nerve cell.
The result much studied at present all shows that the decline of plasmalogen content and many diseases are related such as: Alzheimer
Disease, Parkinson's disease, Zellweger syndrome etc..Wherein Alzheimer disease (AD) is a kind of progressive neurodegenerative disease,
It is the most common dementia.There are positives for the severity and the reduction degree of plasmalogen for being further discovered that alzheimer's disease
The relationship of pass.Therefore many zooperies have been carried out and clinical trial also demonstrate that mild cognitive barrier can be improved in plasmalogen
Hinder, the learning ability and memory of slight Alzheimer's and mouse model.
Ascidian (Ascidians) belongs to Chordata (Chordates), Urochordata (Urochordata)
Ascidiacea (Ascidiacea) is grown on natural sea area attachment pearl shell cage, and about 1600 kinds of the whole world is mainly distributed on
The torrid zone and subtropical seas, ascidian is also widely distributed in China, and resourceful, the coastal area of china ascidian type recorded has 100
More than, and having much is the fixed animal to live of battalion for the peculiar ascidian in China.With land microbial ratio, ascidian grows nonparasitically upon another plant very altogether
Bacterium is resistant to a variety of extreme conditions such as the distinctive with high salt, high pressure in ocean, hypoxemia, low illumination, therefore forms unique metabolism
And physiological property, the metabolite of different chemical structures is produced, provides the work that land Institute of Micro-biology cannot provide for the mankind
Property metabolite, is that the animal kingdom is unique.Therefore the up-and-coming youngster of referred to as biological study, before there is good application
Scape.
Currently, other some marine organisms also have Plasmalogens, the middle promulgated by the State Council of Publication No. CN108276438A
It is disclosed in bright patent and extracts preparation EPA plasmalogen in sea cucumber.The invention is prepared for EPA plasmalogen by phospholipase D, into
One step in isolated phosphatidalcholine (pPC), the phosphatidal ethanolamine (pPE) that carries out component.But the invention
It is only single to be extracted the plasmalogen of EPA class, it is not described the content of EPA class plasmalogen in its sea cucumber, while
The measurement of other kinds of plasmalogen and separation and content is not illustrated.
Summary of the invention
For above-mentioned disadvantage existing in the prior art, the object of the present invention is to provide a kind of rich in a variety of plasmalogens
Ascidian extract and its preparation and analysis method.The present invention prepares the extraction of the ascidian rich in a variety of plasmalogens using ascidian
The lipid metabolism product species of object, ascidian are different from terrestrial life, contain phospholipids compounds more abundant, can be more efficient
Ground obtains Plasmalogens compound.
In order to achieve the above object, the invention adopts the following technical scheme:
A kind of preparation method of the ascidian extract rich in a variety of plasmalogens, comprising the following steps:
(1) prepare fresh ascidian, pre-processed；Fresh true ascidian (Halocynthiaroretzi) is pre-processed, is squeezed
Out moisture, the inedible tissue such as clean ooze, remove internal organ, and shred as uniform fritter, be placed on -80 degree or less cryogenic freezing
Later, it carries out grinding to be homogenized, freeze-dried powder is prepared on freeze drier.For prevent in subsequent extracted step plasmalogen at
Divide Oxidative inactivation, ascidian freeze-dried powder and antioxidant VE dry powder (ratio is 1:1%-2%) are uniformly mixed.
(2) organic solvent extracts, and vacuum concentration obtains the ascidian extract rich in plasmalogen:
(a) ascidian freeze-dried powder made from a certain amount of step (1) is weighed, a small amount of water is added and is diluted, and chloroform-is added
Methanol (2:1, v/v), shakes up concussion, and standing 1-2 hours at room temperature makes demixing of solvents；It is then centrifuged for (6000rpm, 15min), is turned
Supernatant is moved and collected, residue is obtained；
(b) chlorination imitation-carbinol-water (2:1:0.8, v/v/v) in residue, shakes up, and is centrifuged (6000rpm, 15min),
It shifts and collects supernatant；
(c) supernatant for merging (a) and (b) is added chloroform and water that volume ratio is 1:1, shakes, centrifugation；Take bottom
Chloroform mutually into glass tube with cover, is dried up under a nitrogen, is concentrated in vacuo, and the extraction of ascidian plasmalogen can be obtained
Object is stored at -20 DEG C.
In above-mentioned technical proposal, further, the ascidian extract rich in a variety of plasmalogens uses above-mentioned side
Method is prepared.
Further, the ascidian extract rich in a variety of plasmalogens includes 9 kinds of phosphatidyl-ethanolamine acetals
The plasmalogen ingredient of phosphatide and a kind of phosphatidylserine plasmalogen and polyunsaturated fatty acid DHA and EPA.
The present invention also provides a kind of analysis method of ascidian extract rich in a variety of plasmalogens, the ascidian is mentioned
The analysis method of the composition and content that take object is as follows:
Sample uses HCl treatment front and back, and (mass fraction is analyzed for the HCl treatment 5min of 36%-38%) using HPLC
Content；The composition of ascidian extract uses mass spectral analysis.Plasmalogens compound accounting in corresponding phosphatide cpd
Higher, content is about 1.70mg/g dry powder weight；The phosphatidyl-ethanolamine of 9 kinds of different molecular weights is detected in ascidian extract
Plasmalogen (pPE), cation karyoplasmic ratio [M+H]+It is respectively as follows: 776.5 (p18:0/22:6)；752.5(p18:0/20:4)；
750.5(p18:0/20:5)；716.5(p18:0/17:1)；748.5(p16:0/22:6)；722.5(p16:0/20:5)；746.5
(p18:2/20:5)；784.5(p18:0/22:2)；798.5(p20:1/22:6).Numerical value indicates the side chain composition of pPE in bracket,
22:6 shows that, containing DHA (docosahexaenoic acid), 20:5 shows containing EPA (eicosapentaenoic acid).In addition, detecting 1
A phosphatidylserine plasmalogen (pPS), cation karyoplasmic ratio [M+H]+For 826.5 (p18:0/22:2).
Further, the ascidian extract rich in a variety of plasmalogens can be used as raw material for nutraceutical,
The fields such as the relevant health care product of aging disease prevention and cure and drug development.
The beneficial effects of the present invention are:
The present invention compared with sea cucumber and other marine organisms, ascidian it is cheap, aquaculture cost is cheaper, ascidian
It include a variety of plasmalogen ingredients in extract, using ascidian as Plasmalogens compound preparation source with very big excellent
Gesture；The present invention is extracted using certain proportion water mixed organic solvents, and recycles remaining Plasmalogens in supernatant, is shown
It writes and increases extraction efficiency, improve the extracted amount of plasmalogen；Hydrochloric acid is acidified (mass fraction 36%- before high-efficient liquid phase analysis
38%) the 5min time obtains this hair using the type of mass spectral analysis plasmalogen to analyze the content of plasmalogen in extract
It include a variety of plasmalogen ingredients and polyunsaturated fatty acid DHA and EPA in the extract of bright preparation.The method of the present invention preparation
The ascidian extract rich in a variety of plasmalogens can be used as raw material for nutraceutical, the relevant health care of aging disease prevention and cure
The fields such as product and drug development.
Detailed description of the invention
Fig. 1 is the liquid chromatogram of standard items PE.
Fig. 2 is the chromatogram of standard items PE, PS mixed liquor.
Fig. 3 is the chromatogram of ascidian phosphatide analysis.
Fig. 4 is the chromatogram that ascidian phosphatide is acidified 3 minutes post analysis in hydrochloric acid smog.
Fig. 5 is that ascidian phosphatide is acidified the chromatogram analyzed after five minutes in hydrochloric acid smog.
Fig. 6 is that ascidian plasmalogen forms mass spectral analysis.
Specific implementation method:
A kind of preparation method of the ascidian extract rich in a variety of plasmalogens, comprising the following steps:
(1) sample pretreatment: ascidian sample comes from true ascidian.The 10g fresh sample for learning from else's experience pretreated, preprocessing process
Including the inedible tissue such as squeezing the water out, cleaning ooze, remove internal organ；It is cut into uniform fritter with scissors, is placed on -80 DEG C or less
After cryogenic freezing, be placed in mortar carry out grinding be homogenized, further freeze at -80 DEG C, be lyophilized with freeze drier,
Obtain the freeze-dried powder of about 200mg.
(2) preparation of the ascidian extract rich in plasmalogen:
(a) freeze-dried powder about 100mg is taken, 2ml is diluted with water to；
(b) this suspension is fitted into 25ml glass centrifuge tube (centrifuge tube 1), and be added 7.5ml chloroform-methanol (2:
1, v/v) concussion, is shaken up, place 1 hour or so makes demixing of solvents at room temperature；
(c) centrifugation 15min is carried out under the conditions of 6000rpm.After centrifugation, supernatant go to the glass of another 25ml from
In heart pipe (centrifuge tube 2)；
(d) chloroform-methanol-water (2:1:0.8, v/v/v) for adding 9.5ml in centrifuge tube 1, shakes up, 6000rpm centrifugation
15min；
(e) supernatant twice is merged, the chloroform of 5ml and the water of 5ml is added, shaken, centrifugation；
(f) it takes the chloroform of bottom mutually into the glass tubule for having lid, is dried up under a nitrogen, then be concentrated in vacuo preservation
Refrigerator is spent -20.
(a-f) volume of preparation process can amplify.
(3) efficient liquid phase chromatographic analysis of plasmalogen extract
(a) high-efficient liquid phase chromatogram condition
Chromatographic column: Tnature C18Column (4.6 × 250mm of 5um)；Mobile phase is n-hexane: isopropanol: 1.7%
Phosphate aqueous solution=45:48:7 (v/v/v) solution, wherein phosphate aqueous solution is the proportion 50:1 with water and 85% phosphoric acid
(v/v), flow velocity 1ml/min, Detection wavelength is in 205nm.
(b) configuration of standard and sample solution
Phosphatidyl-ethanolamine (PE), phosphatidylserine (PS) standard items (Sigma company) each 5mg are accurately weighed, with just
Hexane dilutes and constant volume is to 5ml, and configuration concentration is the standard solution of 1mg/ml.Weigh three parts of a certain amount of sample, Yi Fenshi
Normal ascidian phospholipid extract, second part is the ascidian phospholipid extract that 3 minutes are acidified under the smog of concentrated hydrochloric acid, third part
It is 5 minutes ascidian phospholipid extracts under the smog of concentrated hydrochloric acid, and is diluted to certain concentration with n-hexane.The mesh of hydrochloric acid acidification
Be that acidolysis plasmalogen forms the products such as the hemolytic phosphatide that can detecte, specific method is that 5 drop hydrochloric acid of drop are placed on test tube cap
In, the test tube for filling sample is upside down in processing and timing in hydrochloric acid smog；
(c) high-efficient liquid phase chromatogram is analyzed
Fig. 1 is that standard items are positive the chromatographic results figure under hexane/isopropyl alcohol/aqueous systems in mobile phase.It can be seen that PE goes out
Peak is more early, about in two minutes or so appearances.
Fig. 2 is standard items in mobile phase n-hexane/isopropanol/phosphate aqueous solution system chromatographic results, standard items mixing
The appearance of liquid is it is obvious that PE retention time is 2.2min, earlier than PS (3min).
It is that sample carries out liquid chromatogram under the dissolution of n-hexane in Fig. 3, can detecte the peak PE, PS is also when retaining
Between (3.7min) appearance (content is lower).Due to there is no to use other standard items as control, other two peaks in ascidian extract
Phospholipid composition it is not qualitative.
In the experiment of Fig. 4, the chromatogram that We conducted samples under the smog of concentrated hydrochloric acid under acidolysis 3 minutes is observed
It is unobvious with the difference of raw sample, illustrate very stable within the limited acidolysis time for ascidian extract plasmalogen.
Fig. 5 be sample acidolysis observe after five minutes as a result, phosphatidyl-ethanolamine plasmalogen (pPE) by hydrochloric acid acidification at
Corresponding hemolytic phosphatide (lyso-PE), by the ratio of computer chromatography peak area, it can be deduced that PE:pPE=5:1 or so, contracting
Aldehyde phospholipids compounds account for relatively high in corresponding phosphatide cpd, and the content of plasmalogen is about 1.70mg/g dry powder
Weight.
(4) mass spectral analysis of ascidian extract plasmalogen composition
(a) mass spectral analysis condition:
Instrument uses MaXis QTOF mass spectrograph (Bruker Daltonics, Billerica, MA USA)；ACQUITY
UPLC liquid chromatograph (Waters, US).Mass Spectrometry Conditions: cation MS scanning, m/z 300-1000, spray voltage
4500V, spraying gas 0.8Bar, dry gas 0.6L/min.Chromatographic condition: BEH C18column (2.1mm × 100mm, 1.7 μm)
(Waters Corp.,Milford,USA)；Mobile phase: A Xiang Weishui, B phase is methanol.Gradient elution program are as follows: 3%B (0.0-
0.5min)；3-80%B (0.5-8.0min)；80-100%B (8.0-14.0min)；100%B (14.0-19.0min)；100-
3%B (19.0-19.1min)；3%B (19.1-22.0min).Column temperature: 30 DEG C；Flow velocity 0.3ml/min, 1 μ l of sample volume.(b) matter
Spectrum analysis result
Figure is the mass spectrometry results of 6 plasmalogens composition.9 kinds of different molecular weights are detected in ascidian extract
Phosphatidyl-ethanolamine plasmalogen (pPE), cation [M+H]+It is respectively as follows: 776.5 (p18:0/22:6)；752.5(p18:0/
20:4)；750.5(p18:0/20:5)；716.5(p18:0/17:1)；748.5(p16:0/22:6)；722.5(p16:0/20:
5)；746.5(p18:2/20:5)；784.5(p18:0/22:2)；798.5(p20:1/22:6).Numerical value indicates pPE's in bracket
Side chain composition, 22:6 show that, containing DHA (docosahexaenoic acid), 20:5 shows containing EPA (eicosapentaenoic acid).In addition,
It detects phosphatidylserine plasmalogen (pPS), cation [M+H]+For 826.5 (p18:0/22:2).PPE each component
Corresponding figure are as follows: Fig. 6 .1, Fig. 6 .2, Fig. 6 .3, Fig. 6 .4, Fig. 6 .5, Fig. 6 .6, Fig. 6 .7, Fig. 6 .8, Fig. 6 .9.Fig. 6 .10 is pPS.
Claims (5)
1. a kind of preparation method of the ascidian extract rich in a variety of plasmalogens, which comprises the following steps:
(1) prepare fresh true ascidian, pre-processed: pre-processing fresh true ascidian includes squeezing the water out, cleaning ooze, remove
Viscera tissue, and shred as uniform fritter, it is placed on after the following freezing of -80 degree, carries out grinding and be homogenized, be then lyophilized and obtain
Ascidian freeze-dried powder uniformly mixes ascidian freeze-dried powder with antioxidant VE dry powder with the mass ratio of 1:1%-2%；
(2) organic solvent extracts, and vacuum concentration obtains the ascidian extract rich in plasmalogen:
(a) water that ascidian freeze-dried powder quality 2%-2.5% is added into the ascidian freeze-dried powder for being mixed with antioxidant VE dry powder carries out
Dilution shakes up, and chloroform and methanol that volume ratio is 2:1 is added, and continues to shake up, and being placed at room temperature for 1-2 hours makes demixing of solvents, it
6000rpm is centrifuged 15min afterwards, shifts and collects supernatant, obtain residue；
(b) chloroform, the first alcohol and water that volume ratio is 2:1:0.8 are added in residue, shakes up, 6000rpm is centrifuged 15min, turns
It moves and collects supernatant；
(c) supernatant for merging (a) and (b) is added chloroform and water that volume ratio is 1:1, shakes, centrifugation；Take the chloroform of bottom
It is mutually dried up under a nitrogen, is concentrated in vacuo, the ascidian extract rich in plasmalogen can be obtained.
2. a kind of ascidian extract rich in a variety of plasmalogens, which is characterized in that use the method as described in claim 1 system
It is standby to obtain.
3. the ascidian extract according to claim 2 rich in a variety of plasmalogens, which is characterized in that the ascidian mentions
Take includes 9 kinds of phosphatidyl-ethanolamine plasmalogens and a kind of phosphatidylserine plasmalogen and polyunsaturated fatty acid in object
The plasmalogen ingredient of DHA and EPA.
4. the ascidian extract according to claim 3 rich in a variety of plasmalogens, which is characterized in that use efficient liquid phase
Chromatography and mass spectrum carry out content and floristic analysing respectively, and the high performance liquid chromatography is with mass fraction before analyzing content
The hydrochloric acid of 36%-38% is acidified 5min to ascidian phospholipid extract.
5. the ascidian extract according to claim 2 rich in a variety of plasmalogens, which is characterized in that can be used as raw material use
In fields such as nutraceutical, the relevant health care product of aging disease prevention and cure and drug developments.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910757992.5A CN110354144B (en) | 2019-08-16 | 2019-08-16 | Sea squirt extract rich in various plasmalogens and preparation and analysis method thereof |
| PCT/CN2020/071031 WO2021031519A1 (en) | 2019-08-16 | 2020-01-08 | Ascidian extract rich in various plasmalogens and preparation and analysis methods therefor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910757992.5A CN110354144B (en) | 2019-08-16 | 2019-08-16 | Sea squirt extract rich in various plasmalogens and preparation and analysis method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110354144A true CN110354144A (en) | 2019-10-22 |
| CN110354144B CN110354144B (en) | 2021-08-17 |
Family
ID=68224660
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910757992.5A Active CN110354144B (en) | 2019-08-16 | 2019-08-16 | Sea squirt extract rich in various plasmalogens and preparation and analysis method thereof |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN110354144B (en) |
| WO (1) | WO2021031519A1 (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111992154A (en) * | 2020-08-20 | 2020-11-27 | 浙江工商大学 | Purification process of plasmalogen |
| CN112255328A (en) * | 2020-09-21 | 2021-01-22 | 河南师范大学 | Optimized method for measuring fatty acids in different tissues of fish body |
| WO2021031519A1 (en) * | 2019-08-16 | 2021-02-25 | 田兵 | Ascidian extract rich in various plasmalogens and preparation and analysis methods therefor |
| CN115192528A (en) * | 2022-07-01 | 2022-10-18 | 国科温州研究院(温州生物材料与工程研究所) | Lung surface active composition containing plasmalogen and preparation method thereof |
| CN115768398A (en) * | 2020-06-30 | 2023-03-07 | 株式会社流变机能食品研究所 | Composition for hair growth and/or hair growth |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108276438A (en) * | 2018-02-02 | 2018-07-13 | 中国海洋大学 | A kind of preparation method and applications of EPA plasmalogens |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007262024A (en) * | 2006-03-29 | 2007-10-11 | Tohoku Univ | Method for extracting plasmalogen-containing lipid, plasmalogen-containing lipid and functional beverage and food |
| JP5662060B2 (en) * | 2010-06-04 | 2015-01-28 | 学校法人帝京大学 | Detection method |
| JP7148053B2 (en) * | 2018-02-28 | 2022-10-05 | エフエムジー＆ミッション株式会社 | Eating and drinking composition and capsule |
| CN111757741A (en) * | 2018-03-08 | 2020-10-09 | 日本药品株式会社 | Process for preparing plasmalogen-containing compositions |
| CN110354144B (en) * | 2019-08-16 | 2021-08-17 | 田兵 | Sea squirt extract rich in various plasmalogens and preparation and analysis method thereof |
-
2019
- 2019-08-16 CN CN201910757992.5A patent/CN110354144B/en active Active
-
2020
- 2020-01-08 WO PCT/CN2020/071031 patent/WO2021031519A1/en active Application Filing
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108276438A (en) * | 2018-02-02 | 2018-07-13 | 中国海洋大学 | A kind of preparation method and applications of EPA plasmalogens |
Non-Patent Citations (3)
| Title |
|---|
| SHINIJI YAMASHITA: "preparation of marine plasmalogen and selective identification o fmolecular species by lc-ms/ms", 《JOURNAL OF OLEO SCIENCE》 * |
| 朱全胜: "3"-甲基-4-二甲氨基偶氮苯对大鼠肝脏磷脂代谢的影响", 《上海医科大学学报》 * |
| 黄佳琪: "海洋水产品中缩醛磷脂的分离纯化及活性探究", 《中国优秀硕士学位论文全文数据库工程科技I辑》 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021031519A1 (en) * | 2019-08-16 | 2021-02-25 | 田兵 | Ascidian extract rich in various plasmalogens and preparation and analysis methods therefor |
| CN115768398A (en) * | 2020-06-30 | 2023-03-07 | 株式会社流变机能食品研究所 | Composition for hair growth and/or hair growth |
| CN111992154A (en) * | 2020-08-20 | 2020-11-27 | 浙江工商大学 | Purification process of plasmalogen |
| CN112255328A (en) * | 2020-09-21 | 2021-01-22 | 河南师范大学 | Optimized method for measuring fatty acids in different tissues of fish body |
| CN115192528A (en) * | 2022-07-01 | 2022-10-18 | 国科温州研究院(温州生物材料与工程研究所) | Lung surface active composition containing plasmalogen and preparation method thereof |
| CN115192528B (en) * | 2022-07-01 | 2023-12-01 | 国科温州研究院(温州生物材料与工程研究所) | Lung surface active composition containing plasmalogens and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021031519A1 (en) | 2021-02-25 |
| CN110354144B (en) | 2021-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110354144A (en) | Rich in the ascidian extract of a variety of plasmalogens and its preparation and analysis method | |
| Gan et al. | Correlations between antioxidant activity and alkaloids and phenols of maca (Lepidium meyenii) | |
| Jim et al. | Stable carbon isotopic evidence for differences in the dietary origin of bone cholesterol, collagen and apatite: implications for their use in palaeodietary reconstruction | |
| Aune et al. | Comparison of oral and intraperitoneal toxicity of yessotoxin towards mice | |
| Mishra et al. | Non-targeted metabolomics and scavenging activity of reactive oxygen species reveal the potential of Salicornia brachiata as a functional food | |
| Li et al. | The major lipid changes of some important diet microalgae during the entire growth phase | |
| Macko et al. | Documenting the diet in ancient human populations through stable isotope analysis of hair | |
| Colonese et al. | The identification of poultry processing in archaeological ceramic vessels using in-situ isotope references for organic residue analysis | |
| Restuccia et al. | Determination of phospholipids in food samples | |
| Leggio et al. | Simultaneous extraction and derivatization of amino acids and free fatty acids in meat products | |
| Kobbi et al. | Purification and recovery of RuBisCO protein from alfalfa green juice: antioxidative properties of generated protein hydrolysate | |
| Song et al. | The optimization of production and characterization of antioxidant peptides from protein hydrolysates of Agrocybe aegerita | |
| Boselli et al. | Determination of phospholipid molecular species in pork meat by high performance liquid chromatography–tandem mass spectrometry and evaporative light scattering detection | |
| Yang et al. | Identification and differentiation of wide edible mushrooms based on lipidomics profiling combined with principal component analysis | |
| CN106191183B (en) | The preparation method and applications of broccoli protein peptides | |
| Kıvrak et al. | Assessment of bioactive compounds and antioxidant activity of Turkey tail medicinal mushroom Trametes versicolor (Agaricomycetes) | |
| Abugri et al. | Fatty acid profiling in selected cultivated edible and wild medicinal mushrooms in Southern United States | |
| Zhao et al. | Tracing the geographical origins of Yesso scallop (Patinopecten yessoensis) by using compound-specific isotope analysis: an approach for overcoming the seasonal effect | |
| Morada et al. | Anti-diabetic polysaccharide from mangrove plant, Sonneratia alba Sm | |
| Saviano et al. | Metabolite variation in three edible Italian Allium cepa L. by NMR-based metabolomics: A comparative study in fresh and stored bulbs | |
| Girjal et al. | Antioxidant properties of the peptides isolated from Ganoderma lucidum fruiting body | |
| Fernandes et al. | Insights on the intestinal absorption of chlorophyll series from microalgae | |
| Jančić et al. | Biologically active compounds and antioxidant capacity of Cichorium intybus L. leaves from Montenegro | |
| Rey et al. | Applications of lipidomics in marine organisms: progress, challenges and future perspectives | |
| CN110554129B (en) | Screening method of potential anti-inflammatory active ingredients in extra-virgin olive oil |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |